NCT07214779View on ClinicalTrials.gov

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

466

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

November 15, 2028

Study Completion Date

May 14, 2029

Conditions
Ovarian Cancer
Interventions
DRUG

INCB123667

Oral; tablet

DRUG

Investigator's choice of chemotherapy

The investigator will select the chemotherapy in accordance with the protocol-defined requirements. The possible choices as defined by the protocol:

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
collaborator

ENGOT Foundation

UNKNOWN

collaborator

GOG Foundation

NETWORK

lead

Incyte Corporation

INDUSTRY